> In conclusion, we present data suggesting that the 501Y.V2 variant first detected in South Africa is able to escape the neutralizing antibody response elicited by natural infection with earlier variants.
We expect data in the next weeks from phase 3 vaccine trials being conducted in South Africa. If the variant does have an effect on vaccine efficacy, then there may be a signal in the data from these clinical trials.
Vaccine efficacy is still inconclusive but we’ll know soon.